FogPharma

FogPharma is a biotechnology company based in Cambridge, Massachusetts. The company employs 146 people and generates $5.5 million in annual revenue. FogPharma focuses on developing a new class of drugs known as HeliconTM peptides. These peptides are designed to overcome the limitations of current precision medicines by combining the targeting capabilities of monoclonal antibodies with the cell-penetrating properties of small molecules. This innovative approach aims to enable the treatment of nearly all disease drivers with unprecedented speed and efficiency. FogPharma's HeliconTM peptides represent a groundbreaking advancement in drug development, offering the potential to revolutionize healthcare. Their unique properties promise to expand the scope of druggable targets, leading to new therapies for a wide range of diseases. For more information about FogPharma and its innovative drug development platform, please visit fogpharma.com.